AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has been withdrawn. The decision leaves no remaining challenges pending against the company’s U.S. Patent No. 12,138,276, a patent covering halogenated psilocybin derivatives. The petition had originally been filed by Gilgamesh Pharmaceuticals, which was later acquired by AbbVie Inc. in a deal worth up to 1.2 billion dollars centered on bretisilocin, also known as GM 2505. After the acquisition, AbbVie was identified as a real party in interest in the patent proceeding. In November, AbbVie’s counsel requested withdrawal of the petition. The U.S. Patent Trial and Appeal Board granted that request. For Enveric, the outcome represents more than a procedural win. It removes a cloud that hung over a patent potentially relevant to bretisilocin and reinforces the strength of its intellectual property est...